Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaji Kumar

Showing results (171-180 of 515) with videos related to

Pageof 52
Sort By:
Bone Marrow Transplantation|March 17, 2022
Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplantDhauna Karam, Morie Gertz, Martha Lacy, et al.
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion|February 15, 2017
Consensus in the Management of Multiple Myeloma in India at Myeloma State of the Art 2016 ConferenceUday Yanamandra, Navin Khattry, Shaji Kumar, et al.
British Journal of Haematology|October 9, 2003
Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myelomaMichael A Thompson, Thomas E Witzig, Shaji Kumar, et al.
European Journal of Haematology|May 19, 2010
Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myelomaFrancesca Gay, S Vincent Rajkumar, Patrizia Falco, et al.
Hematological Oncology|September 23, 2023
Venetoclax in biomarker-selected multiple myeloma patients: Impact of exposure on clinical efficacy and safetyMohamed Badawi, Sheryl Coppola, Doerthe Eckert, et al.
Targeted Oncology|December 13, 2016
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance)Joleen M Hubbard, Michelle R Mahoney, William S Loui, et al.
Mayo Clinic Proceedings|April 17, 2018
Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic ReviewRobert A Kyle, Dirk R Larson, Ellen D McPhail, et al.
Leukemia|May 17, 2019
Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m<sup>2</sup> vs. twice-weekly 27 mg/m<sup>2</sup> carfilzomib (randomized A.R.R.O.W. study)Philippe Moreau, Shaji Kumar, Ralph Boccia, et al.
Archives of Dermatology|October 19, 2005
Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantationMartha Q Lacy, William J Hogan, Morie A Gertz, et al.
Leukemia & Lymphoma|March 31, 2009
Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myelomaLuciano J Costa, Shaji Kumar, Angela Dispenzieri, et al.
Pageof 52

Showing results (171-180 of 515) with videos related to

Sort By:
Pageof 52
Bone Marrow Transplantation|March 17, 2022
Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplantDhauna Karam, Morie Gertz, Martha Lacy, et al.
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion|February 15, 2017
Consensus in the Management of Multiple Myeloma in India at Myeloma State of the Art 2016 ConferenceUday Yanamandra, Navin Khattry, Shaji Kumar, et al.
British Journal of Haematology|October 9, 2003
Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myelomaMichael A Thompson, Thomas E Witzig, Shaji Kumar, et al.
European Journal of Haematology|May 19, 2010
Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myelomaFrancesca Gay, S Vincent Rajkumar, Patrizia Falco, et al.
Hematological Oncology|September 23, 2023
Venetoclax in biomarker-selected multiple myeloma patients: Impact of exposure on clinical efficacy and safetyMohamed Badawi, Sheryl Coppola, Doerthe Eckert, et al.
Targeted Oncology|December 13, 2016
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance)Joleen M Hubbard, Michelle R Mahoney, William S Loui, et al.
Mayo Clinic Proceedings|April 17, 2018
Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic ReviewRobert A Kyle, Dirk R Larson, Ellen D McPhail, et al.
Leukemia|May 17, 2019
Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m<sup>2</sup> vs. twice-weekly 27 mg/m<sup>2</sup> carfilzomib (randomized A.R.R.O.W. study)Philippe Moreau, Shaji Kumar, Ralph Boccia, et al.
Archives of Dermatology|October 19, 2005
Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantationMartha Q Lacy, William J Hogan, Morie A Gertz, et al.
Leukemia & Lymphoma|March 31, 2009
Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myelomaLuciano J Costa, Shaji Kumar, Angela Dispenzieri, et al.
Pageof 52